Beijing Tiantan Biological Products (600161) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
24 Oct, 2025Executive summary
Revenue for the first nine months of 2025 reached RMB 4.47 billion, up 9.62% year-over-year, but net profit attributable to shareholders fell 22.16% to RMB 818.69 million.
Q3 net profit dropped 42.84% year-over-year, mainly due to lower sales prices and increased credit impairment losses.
Financial highlights
Q3 revenue: RMB 1.35 billion, up 9.96% year-over-year; Q3 net profit: RMB 186.12 million, down 42.84%.
Basic and diluted EPS for Q3: RMB 0.09, down 42.84% year-over-year.
Operating cash flow for the first nine months: RMB 116.90 million, down 91% year-over-year.
Total assets at Q3-end: RMB 16.55 billion, up 4.29% from year-end 2024.
Outlook and guidance
Management attributes profit decline to lower sales prices and stricter credit policies, leading to higher credit impairment losses.
Latest events from Beijing Tiantan Biological Products
- Revenue up 9.47%, net profit down 12.88%, with higher dividends and ongoing expansion.600161
H1 202522 Dec 2025 - Revenue up 7.84%, but net profit down 22.90% and operating cash flow negative.600161Q1 202522 Dec 2025
- Net profit jumped 39.42% on strong sales and plasma collection growth.600161H2 202422 Dec 2025
- Net profit rose 18.52% year-over-year, but Q3 profit declined 7.44%.600161Q3 202422 Dec 2025
- Net profit surged 28.12% on higher margins and robust plasma business growth.600161H1 202422 Dec 2025